Management of Growth Disorders in Puberty: GH, GnRHa, and Aromatase Inhibitors: A Clinical Review
Endocrine Reviews · 12.01.2023 · 44 (1) · 1-13
DOI: 10.1210/endrev/bnac014 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrine Reviews, online erschienen am 27.05.2022. Verfasst von Nelly Mauras und 2 weiteren Autor:innen. Beteiligte Einrichtung: Nemours Children's Health Jacksonville, FL, USA. Hauptthemen laut MEDLINE: Aromatase Inhibitors, Human Growth Hormone. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 99 Literaturangaben.
Abstract (Originalsprache)
Pubertal children with significant growth retardation represent a considerable therapeutic challenge. In growth hormone (GH) deficiency, and in those without identifiable pathologies (idiopathic short stature), the impact of using GH is significantly hindered by the relentless tempo of bone age acceleration caused by sex steroids, limiting time available for growth. Estrogen principally modulates epiphyseal fusion in females and males. GH production rates and growth velocity more than double during puberty, and high-dose GH use has shown dose-dependent increases in linear growth, but also can raise insulin-like growth factor I concentrations supraphysiologically, and increase treatment costs. Gonadotropin-releasing hormone analogs (GnRHas) suppress physiologic puberty, and when used in combination with GH can meaningfully increase height potential in males and females while rendering adolescents temporarily hypogonadal at a critical time in development. Aromatase inhibitors (AIs) block androgen to estrogen conversion, slowing down growth plate fusion, while allowing normal virilization in males and stimulating longitudinal bone growth via androgen receptor effects on the growth plate. Here, we review the physiology of pubertal growth, estrogen and androgen action on the epiphyses, and the therapeutic impact of GH, alone and in combination with GnRHa and with AIs. The pharmacology of potent oral AIs, and pivotal work on their efficacy and safety in children is also reviewed. Time-limited use of AIs is a viable alternative to promote growth in pubertal males, particularly combined with GH. Use of targeted growth-promoting therapies in adolescence must consider the impact of sex steroids on growth plate fusion, and treatment should be individualized.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nemours Children's Health Jacksonville, FL, USA.
- Nemours Children's Health Wilmington, DE, USA.
- University of Chile, Santiago, Chile.
ORCID-Profile: Nelly Mauras, Veronica Mericq
Zitieren
APA
Mauras, N., Ross, J., & Mericq, V. (2023). Management of Growth Disorders in Puberty: GH, GnRHa, and Aromatase Inhibitors: A Clinical Review. Endocrine Reviews, 44(1), 1-13. https://doi.org/10.1210/endrev/bnac014
Vancouver
Mauras N, Ross J, Mericq V. Management of Growth Disorders in Puberty: GH, GnRHa, and Aromatase Inhibitors: A Clinical Review. Endocrine Reviews. 2023;44(1):1-13. doi:10.1210/endrev/bnac014
BibTeX
@article{Mauras2023,
author = {Mauras, Nelly and Ross, Judith and Mericq, Veronica},
title = {Management of Growth Disorders in Puberty: GH, GnRHa, and Aromatase Inhibitors: A Clinical Review},
journal = {Endocrine Reviews},
year = {2023},
volume = {44},
number = {1},
pages = {1--13},
doi = {10.1210/endrev/bnac014}
}
EUVIMED